GLP-1 Drugs

A growing body of research suggests that GLP-1 drugs do more than control appetite and blood sugar. They could also fight inflammation

The weight you lose and the nausea you experience from GLP-1 drugs may be linked to common gene variants, but they can’t fully explain why some people lose more weight than others

This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks

“Imitation” drugs, unexpected benefits, serious pitfalls—here’s what comes next as GLP-1 medications continue to rise in popularity

Three types of diabetes medication are improving the outlook for patients with kidney disease

A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce drug- and alcohol-related overdoses and deaths

A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications

The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than current treatments. But experts wonder how much is too much

Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.

A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising

The first GLP-1 pills for weight loss are hitting U.S. pharmacies. But how will they be prescribed?